Synlogic, Inc.(SYBX)

Description: Synlogic, Inc., formerly Mirna Therapeutics, Inc., is engaged in the development of a novel class of living treatments, Synthetic Biotic medicines. The Company uses its proprietary Synthetic Biotic development platform. Its pipeline includes Synthetic Biotic medicines for the treatment of rare genetic diseases, such as Urea Cycle Disorder (UCD) and Phenylketonuria (PKU). It is also focused on Synthetic Biotic medicines to address other conditions, including inflammatory bowel disease , cancer and metabolic conditions, such as diabetes and obesity. The Company’s synthetic biotic medicines leverages the tools and principles of synthetic biology to genetically reengineer probiotic microbes to perform or deliver critical functions missing or damaged due to disease. The Company’s pipeline includes synthetic biotic medicines for the treatment of inborn errors of metabolism (IEM). It is developing SYNB1020 for the treatment of UCD and HE. It is developing SYNB1618 for the treatment of PKU.

---

Keywords: Cancer Biology Disease Diabetes Obesity Inflammatory Bowel Disease Metabolism Genetic Diseases Synthetic Biology Rare Genetic Diseases Inborn Errors Of Metabolism Phenylketonuria Pku Rare Genetic Disease Urea Cycle Intellectual Disability Newborn Screening

---

Home Page: www.synlogictx.com

SYBX Technical Analysis

301 Binney Street
Cambridge, MA 02142
United States
Phone: 617 401 9975

---

Officers

Exchange: NASDAQ

Country: US

Currency: US Dollar ($)